Relative effectiveness and durability of booster doses of SARS-CoV-2 vaccines: A systematic review and meta-analysis

Author:

Liu Di,Jiang Yiwen,Wang Shiyu,Li Fuxiao,Lin Tengfei,Li Bingli,Zhao Ziyi,Yun Qingping,Peng Nana,Cai Jiaxin,Zheng Lingling,Jia Yuanxi,Yang Zuyao,Sha Feng,Yang Zhirong,Tang Jinling

Abstract

<p>Billions of people worldwide have received booster doses of SARS-CoV-2 vaccines. Continuous monitoring of the relative vaccine effectiveness (rVE) and durability of booster vaccination over previous vaccinations is important for developing vaccination strategies during the post-pandemic era. We conducted a systematic review and meta-analysis of trials and observational studies to determine the rVE of the 1<sup>st</sup> booster over no booster and that of the 2<sup>nd</sup> booster over the 1<sup>st</sup> booster. Three trials and 91 observational studies were included in this systematic review. For the 1<sup>st</sup> booster homologous vaccination, the rVE at a median of 9 weeks after booster vaccination was 66.9% (95% confidence interval: 59.8%, 72.7%), 75.9% (62.6%, 84.5%), 74.1% (66.9%, 79.8%), 86.1% (78.7%, 90.9%) and 84.2% (78.3%, 88.5%) against overall infection, symptomatic infection, hospital admission, severe infection and COVID-19-related death, respectively. The rVE against overall infection was affected by variants of concern and vaccine types and waned by average of 4.3% (3.3%, 5.4%; <i>P-trend</i><0.01) per week. Heterologous regimens for the 1<sup>st</sup> booster vaccination demonstrated effectiveness comparable to that of homologous regimens. The rVE of the 2<sup>nd</sup> booster homologous vaccination at a median of 7 weeks after booster vaccination was 41.9% (31.2%, 51.0%), 53.1% (24.5%, 70.9%), 60.6% (55.3%, 65.3%), 56.4% (45.3%, 65.2%) and 68.2% (51.2%, 79.2%) against the five outcomes above, respectively, with no significant decrease in the rVE of 2<sup>nd</sup> booster vaccination. In conclusion, both the 1<sup>st</sup> and 2<sup>nd</sup> booster homologous vaccinations provided additional protection against mild and severe infections. The rVE of the 1<sup>st</sup> booster rapidly waned over time. The rVE of the 2<sup>nd</sup> booster, including heterologous vaccination, its durability and the sources of heterogeneity, however, remains uncertain and more relevant studies are needed.</p>

Publisher

Innovation Press Co., Limited

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3